PUFA for Human Health: Diet or Supplementation?

Author(s): P. Abete, G. Testa, G. Galizia, D. Della-Morte, F. Cacciatore, F. Rengo

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 36 , 2009

Become EABM
Become Reviewer

Abstract:

Large doses of omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are used to treat several diseases including hypertriglyceridemia in humans. Modest levels of EPA and DHA may be obtained from food, particularly from fatty fish. This review presents the literature examining the differences between omega-3 fatty acid dietary supplementation and prescribed omega-3-acid ethyl esters (P-OM3). Reports published between 1995 and 2007 containing sources, recommended intake, and differences in the various formulations of omega-3 fatty acids were sought in PubMed and the Food and Drug Administration (FDA) Websites. However, lack of head-to-head clinical trials using both P-OM3 and dietary-supplement omega-3 fatty acids is the greatest limitation of this review. Although many kinds of omega-3 fatty acid dietary supplements are available, the efficacy, quality, and safety of these products are questionable because they are beyond any pharmaceutical control. Thus, P-OM3 is the only FDA approved omega-3 fatty acid product which is available in the United States as an adjunct to diet to improve human health.

Keywords: Omega-3 fatty acids, diet, supplementation, triglycerides

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 36
Year: 2009
Page: [4186 - 4190]
Pages: 5
DOI: 10.2174/138161209789909665
Price: $65

Article Metrics

PDF: 8